<DOC>
	<DOCNO>NCT00298610</DOCNO>
	<brief_summary>The purpose study determine GMP IV Artesunate metabolize cleared individual uncomplicated malaria infection determine fast eliminate malaria infection body .</brief_summary>
	<brief_title>Safety Efficacy Study IV Artesunate Treat Malaria</brief_title>
	<detailed_description>This unblinded non-randomized phase II pharmacokinetic study new GMP formulation intravenous artesunate . Artesunate use throughout Asia Africa many year . Its overall efficacy associate ability lower parasitemia well establish . To date , pharmacokinetic study do Africa use GMP ( Good Manufacturing Practices ) -produced drug . The objective study show GMP IV artesunate rapidly clear parasites Adult Kenyan population malaria pharmacokinetic profile drug approximates population adult test ( Asians North Americans ) .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>Adult male &amp; nonpregnant female , 1865 year Fever , define &gt; 37.5ÂºC , current illness , history ( within last 48 hour ) fever . Diagnosis falciparum malaria , great equal 200 parasites/uL Able communicate well investigator comply requirement entire study . Willing admitted period drug administration and/or follow ( return hospital ) Provision write informed consent participate show signature inform consent form . Administration investigational drug period 0 16 week entry study . The use medication period 0 14 day ( prescribed drug ) 0 5 day ( OTC ) entry study ( include herbal dietary supplement ) , except deem principal investigator / clinical investigator interfere outcome study . Existence surgical medical condition , judgment clinical investigator , might interfere distribution , metabolism excretion drug . History serious adverse reaction hypersensitivity study drug follow treatment . Mixed malaria infection ( malaria falciparum malaria monoinfection detect screen blood smear ) Severe falciparum malaria ( define WHO ; Attachment 1 ) . Donation loss great 400 ml blood period 0 12 week entry study , Transfusion blood within past 30 day . Refusal prevent pregnancy 14 day trial Pregnancy define clinically positive urine BHCG time screening , nurse mother . Laboratory evidence history significant cardiovascular , liver renal functional abnormality , opinion investigator would place increase risk . Specifically , follow serve exclusionary lab value : Creatinine &gt; 1.4 x ULN ( &gt; 2.0 mg/dL ) Glucose &lt; LLN ( 65mg/dL ) AST , ALT &gt; 3x ULN ( 120 U/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Uncomplicated Malaria</keyword>
	<keyword>GMP artesunate</keyword>
</DOC>